metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
versus BSC
	avelumab alone
	JAVELIN Bladder 100 (all population), 2020 N Engl J Med 2020 Sep 24;383(13):1218-1230. International Journal of Clinical Oncology NCT02603432	RCT	mUC - M - all population	avelumab	BSC	as first line therapy, previously untreated locally advanced or metastatic urothelial carcinoma whose disease did not progress on induction chemotherapy	350 / 350	some concern	conclusif	demonstrated 31 % decrease in deaths (OS),deaths (OS) (PE) suggested 24 % decrease in deaths (OS) (extension),deaths (OS) (extension) suggested 46 % decrease in PFS (extension),PFS (extension) suggested 38 % decrease in progression or deaths (PFS),progression or deaths (PFS)
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
versus BSC
	avelumab alone
	JAVELIN Bladder 100 (PDL1>25%), 2020 N Engl J Med 2020 Sep 24;383(13):1218-1230. NCT02603432	RCT	mUC - M - PDL1 positive	avelumab	no treatment	previously untreated locally advanced or metastatic urothelial carcinoma whose disease did not progress on induction chemotherapy	189 / 169	some concern	conclusif	demonstrated 44 % decrease in deaths (OS),deaths (OS) (PE) suggested 31 % decrease in deaths (OS) (extension),deaths (OS) (extension) suggested 54 % decrease in PFS (extension),PFS (extension) suggested 44 % decrease in progression or deaths (PFS),progression or deaths (PFS)